The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver failure, lung failure, cardiac arrest, aspiration pneumonia and shock.

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on the body, researchers say. The analysis, involving about two million people,